IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A review on personalized medicine: Tailoring treatment based on Individual genetic makeup

[1]S. Shoba, [2]F. Nishvanth, [3]K. Kamalesh, [3]D. Sakthivel

[1]Professor and Head, [2]Assistant Professor cum Ph. D research scholar, [3]B. Pharm Student
[1]Department of Pharmacology,
[1] Adhiparasakthi College of Pharmacy (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai-32)
Melmaruvathur – 603319, Tamil Nadu, India.

Abstract: Medical care is no longer a one-size-fits-all endeavor. There is a problem with the traditional or present systems of medical care because they were developed and tested on large groups of people. Consequently, the prescriptions prescribed are not suitable for every person. Personalized medicine is the revolutionizing healthcare by tailoring treatment to the individual genetic makeup of patients. Personalized medicine is a translational approach that utilizes an individual's genetic profile to guide illness prevention, diagnosis, and treatment choices. The human genome project data is being used to enhance personalized treatment. "Personalized" medicine is beneficial over "individualized" medicine as it suggests that future hazards may be predicted based on the individual's genes. The advancement of technology for personalized medicine depends heavily on standardization, integration, and harmonization. This review explores the historical context, and current application of personalized medicine. It also examines future prospects and the ethical, legal, and social implications of this innovative approach. Despite the challenges, personalized medicine holds the promise of significantly improving patient outcomes by offerings more effective and targeted therapies.

Index Terms **– Personalized medicine, Genetic make-up, Gene sequence.**

INTRODUCTION

The personalized medicine is the term in which a medical model that deals with customization of health-care, therapies with decisions and practices being tailored to be individual patient by use of genetic or other information [1]. The goal of personalized medicine is to provide the therapeutic strategy based on a person's phenotype and genotype at the right time. The terms used interchangeably for personalized medicine are 'precision', 'individualized' and 'stratified' medicine in accordance with the National Research Council. Personalized medicine is often referred to as P4 medicine, i.e., predictive, preventive, personalized and participatory [2].

Fig 1. Concept of P4 medicine.

The concept of P4 medicine is thus mainly based on the use of large volumes of data, mostly biological (omics data). This is particularly the case for personalized medicine, which is one of the foundations of P4 medicine. The US National Human Genome Research Institute defines personalized medicine as "an emerging practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease. Knowledge of a patient's genetic profile can help doctors select the proper medication or therapy and administer it using the proper dose or regimen" (National Human Genome Research Institute, n.d.). It is specified that "personalized medicine is being advanced through data from the Human Genome Project," highlighting the crucial importance of genetics to this approach. Personalized medicine offers an excellent chance to go beyond "one-size-fits-all" approaches to diagnosis, drug therapy and prevention. Although we are all the same, we are also all unique. An application of medication that ignores these differences cannot be any more valid. Genomic analysis allows us to predict disease risk with great precision [3]. In personalized medicine, genomics plays a major role in selecting preventative plans suitable

to the individual. It also helps for choosing a right medicine at the right time in some cases for individuals. The revolution in genomics enables to make a Personalized predictions about their disease risk by taking a closer look at them molecularly, so peoples can choose a preventive plan that suits for the lifestyle. So, genomics plays a vital role in the development of Personalized medicine. In Personalized medicine, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient's genetic content or other molecular or cellular analysis. The use of genetic information has played a major role in certain aspects of personalized medicine (e.g. pharmacogenomics), and the term was first coined in the context of genetics, though it has since broadened to encompass all sorts of personalization measures, including the use of proteomics, imaging analysis, nanoparticle-based theranostics, among others [4].



Fig 2. Basic strategy of personalized medicine.



Fig 3. Major steps involved in personalized medicine.

History:

Individual targeted medicine was originally documented thousands of years ago. Since then, other therapy approaches have been developed. Conventional remedies, however, do not take into account an individual's idiosyncrasy or genetic make-up, and consequently fail to be beneficial in some circumstances. The need for more precise and effective therapy led to the creation of a scientific branch known as "personalized medicine" throughout time. Personalized medicine has been recognized as the next generation of diagnosis and therapy as a result of significant technical developments in this field. Although personalized medicine has received a lot of attention in recent years, it still faces a number of challenges in clinical practice [5].



Fig 4. Personalized medicine: from the ancient times to a promising future.

NEED OF THE STUDY.

The establishment of large hospitals where hundreds to thousands of patients are treated, it has created a serious problems of biomedical waste management. The seriousness of improper biomedical waste management was brought to the light during summer 1998. In India studies have been carried out at local / regional levels in various hospitals, indicate that roughly about 1-5 kg/bed/day to waste is generated. Among all health care personnel, ward boys, sweepers, operation theatre & laboratory attendants have come into contact with biomedical waste during the process of segregation, collection, transport, storage & final disposal. The knowledge of medical, paramedical staff & ward boys, sweepers about the biomedical waste management is important to improve the biomedical waste management practices. The biomedical waste requiring special attention includes those that are potentially infectious, sharps, example needle, scalpels, objects capable of puncturing the skin, also plastic, pharmaceutical & chemically hazardous substances used in laboratories etc.

Benefits:

Personalized Medicine has the potential to offer improved medication selection and targeted therapy, reduce adverse effects, increase patient compliance, shift the goal of medicine from reaction to prevention, improve cost effectiveness, and increase patient confidence post-marketing by approving novel therapeutic strategies and altering the perception of medicine in the healthcare system.

1.Specific disease diagnosis:

One of the key advantages of personalized medicine is its ability to detect and diagnose diseases in a highly specific manner.

2.Customized drug dosage:

Personalized medicine also enables genomic analysis to reveal genetic variations that can guide drug dosage, maximizing drug benefits while minimizing side effects.

3.Disease prevention:

Personalized medicine can also be applied in disease prevention by analyzing a patient's susceptibility to certain illnesses through sequencing technologies.

4.Reduced trial-and-error prescriptions:

With personalized medicine, the need for trial-and-error prescriptions is greatly reduced. But unfortunately, such prescriptions can prove ineffective and quite costly.

5.Enhanced medication adherence:

Personalized medicine can enhance medication adherence by reducing side effects and increasing efficacy. Patients tend to comply better with their medications when they become aware of their genetic

Advantages:

1. Targeted Treatments:

One of the primary advantages of personalized medicine is the possibility to tailor treatments to each patient's specific needs. As just by considering the individual's genetic makeup, doctors can create the most effective medications and therapies, thus, minimizing trial and error in treatment plans. This customized strategy improves the treatment outcomes amazingly and reduces the risk of antagonistic reactions.

2. Prevention And Early Detection:

Personalized medicine enables early detection and prevention of diseases, through the use of genetic testing to detect an individual's predilection to certain diseases, and that in fact allows for proactive interventions and lifestyle modifications to prevent or delay the beginning of these conditions.

3. Patient Empowerment:

A well-prepared personalized medicine case study shows the impact of personalized medicine on active participants through their healthcare journey. Patients who understand their genetic and environmental factors can make informed decisions about their lifestyle choices, treatment options, and disease management strategies.

4. Cost-Effective Healthcare:

Although personalized medicine requires an upfront investment in genetic testing and analysis, however, it has the potential to reduce healthcare cost in the long run.

Disadvantages:

1. Limited Availability and Accessibility:

Personalized medicine is still in its early stages of development and implementation, moreover, cannot be something that is usable in a remote situation. That is why not all healthcare facilities have access to the required infrastructure, knowledge, and technological advancements required for personalized medicine. And this by default limit availability and make it difficult for individuals in remote or underserved areas to use this approach.

2. Ethical and Privacy Concerns:

This is a huge red flag in the world of personalized medicine and medicine in general, as personalized medicine relies heavily on genetic data and personal information to function, raising concerns about privacy and potential misuse. Therefore, protecting this data from unauthorized access and ensuring ethical practices in its usage become critical considerations in the implementation of personalized medicine.

3. Complex Regulatory Landscape:

Personalized medicine presents unique regulatory challenges, due to the nature of personalized treatments, which may involve the growth of new drugs or diagnostic tools, that require strong and flexible regulations to support innovation while ensuring patient safety. Still, developing and implementing such regulations can be a lengthy and complex process, blocking the common adoption of personalized medicine.

4. Expensive and Time-consuming:

It involves various processes, including genetic testing, data analysis, and treatment customization, and these procedures come with an expensive cost and time-consuming, limiting their accessibility to a large section of the population. Therefore, the cost of genetic testing and the infrastructure required for analysis can be unaffordable and may not be covered by some healthcare insurance.

BACKGROUND AND THEORETICAL FRAMEWORK

To develop an integrative framework of personalized medicine, by focusing on the following concrete goals:

1. Developing interdisciplinary and translational research networks for researchers, to develop innovative strategies and health care approaches in the area of personalized medicine.
2. Developing risk-factor based models for personalized medicine approaches that are no longer defined within existing classification and diagnostic systems, but are tailored to individualized risk factors of patients.
3. Assembling databases of genetic, biomedical, and behavioural data in cohort studies for testing generic and disease specific personalized medicine model.
4. Developing innovative methodological approaches of testing specific personalized medicine models from a genomic, social, epidemiological, and/or statistical view.
5. Conducting interdisciplinary and translational research into personalized medicine with a broad range of biomedical, chemical, technological, and social sciences.
6. Evaluating the additional contribution and cost-effectiveness of personalized medicine approaches (eg, tailored vs non-tailored care, patient involvement).
7. Implementing broad strategies of personalized medicine and participatory health care into regular clinical care (eg, personalized risk-factor based approaches of tailored care for various conditions). [6]

Genomics and the human genome project

The term genomic was coined to describe the newly emerging science of (genome) mapping, sequencing, and data processing. According to scientists, the human body has 10 to 20 trillion cells. Each cell is unique and acts differently, although they all follow the same basic structure. The blueprint is known as the nucleus, and the structure is known as chromosomes. They are the basic structure of DNA.

The genome is a collection of DNA from all animals, including humans. Humans have around 3 billion letters of DNA in their genome, all of which are G, T, and C. The Human Genome Project was designed to organize it sufficiently to read all 3 billion letters once and for all, and to make that fundamental information about the human blueprint available to all scientists worldwide. One of the project's highlights was the first successful sequencing of the human genome. They organized the three billion letters that make up the reference human genome sequence.

The Human Genome Initiative (HGP) was an international scientific research initiative that attempted to identify and map all of the genes in the human genome on both a physical and functional basis. This large-scale project is focused on isolating and 2/8 studying the genetic material contained in DNA. With the exception of physical accidents, almost all human medical illnesses are caused by changes. HGP's three main goals are to determine the sequence of the three billion base pairs that make up human DNA, to identify all of the estimated genes in human DNA, and to record all of this information in databases.

The Human Genome Project (HGP) was an international, collaborative research endeavor aimed at mapping and understanding all human genes. The collection of all of our genes is referred to as our "genome." It is significant because it uses DNA information to develop revolutionary approaches for treating, curing, or even preventing the hundreds of diseases that afflict humanity.

Technological Advances Enabling Personalized Medicine

There are a number of very recent research and clinical activities that are charting new territory for personalized medicine.

1.Patient-Derived Cellular Avatars

It is now possible to harvest cells from individuals and use pluripotency induction (i.e., induced pluripotent stem cell or 'iPSC') methods on those cells to generate additional cell types of relevance to a patient's condition without having to directly biopsy the affected tissue. This allows researchers to essentially develop a 'disease in a dish' cellular model of a patient's condition. These in vitro cellular 'avatars' can be studied to identify key molecular pathologies that might give an indication as to how best to treat an individual patient of interest. The use of iPSC technologies in this manner can be extended with a few additional, very recently developed, technologies to create even better models of an individual's condition.

2. Intensive Personalized Health Monitoring

The availability of inexpensive genotyping and sequencing technologies is allowing individuals and their health care providers to assess their genetically-mediated risk for disease and/or make a genetic diagnosis if they are already diseased. In addition, given the availability of health monitoring devices, online-ordered blood-based clinical assays, inexpensive imaging devices, etc. it is possible to continuously, or near continuously, monitor aspects of an individual's health.

3. Digital Therapeutics and Personalized App Content

The wide use of smart phones has attracted the interest of many researchers in the health professions as a vehicle for not only collecting health data through various 'apps' but also to provide advice, feedback, coaching, imagery, music, text-messages, or connections with other resources, that could benefit an individual with a particular condition or disease. This has led to the emergence of the concept of a 'digital therapeutic:' a smart phone app designed to treat and bring relief to an individual affected by a medical or psychological condition.

4. Artificial Intelligence

The use of AI treatment planning in personalized medicine is a powerful tool due to AI's analytical capabilities such as prediction, data integration, and reasoning about underlying patterns.AI can collect information from diverse sources, including people of varying ages, genders, and health conditions. This enables the development of personalized treatment plans tailored to each individual's specific needs. When analysing biomedical data, important techniques include machine learning (ML) and deep learning (DL). These methods have shown promising results in predicting disease risks with greater accuracy.ML algorithms can assess diverse patient data, such as clinical, genomics, metabolomics, imaging, claims, experimental, nutrition, and lifestyle. In particular, genome sequencing and phenotyping are two areas where ML is making significant advances. [7]

APPLICATIONS OF PERSONALIZED MEDICINE

Oncology

Personalized medicine (PM) has revolutionized oncology management in high human development indexed countries. By interrogating both disease and host factors through a variety of tools, oncologists have been able to better target an individual's cancer, leading to improved outcomes.

In the past two decades, the disciple of oncology in high-income countries has evolved from hematoxylin and eosin (H&E) stains to advanced diagnostic platforms. These basic science-driven advances have led to the advent of PM. It is now realized that cancers, even those from the same tissue of origin that appear identical under the microscope, are not necessarily the same. Several oncolytics have been approved in the USA and the European Union based on biomarkers alone in a tissue of origin agnostic fashion. These "targeted" agents are generally vastly more effective than conventional chemotherapy with less toxicity and a great chance of long-term survival. All hosts are not the same either; the most rudimentary examples of this are in the metabolism of irinotecan, 5-fluorouracil (5-FU) and underlying autoimmune conditions. Even the microbiome and the use of antibiotics may influence the effectiveness of immunotherapy. By better understanding both cancer and host-related factors, and how these interplay, PM has revolutionized oncology improving both quantity and quality of life. [8]

Colorectal cancer is a frequently used and well-known model in which tumor-tailored treatment has already been implemented. In colorectal cancers, the stepwise accumulation of genetic and epigenetic events leading to carcinoma formation is well known. This has identified prognostic and predictive biomarkers such as KRAS (Kirsten Rat Sarcoma virus) and microsatellite instability (MSI), guiding targeted treatment choices in the current standard of care. [9]

Cardiovascular Diseases

It will be possible to use human pluripotent stem cells (hPSCs) in cardiovascular clinical care by developing isogenic hPSC cell lines as a control for hPSCs with disease-specific mutations and a large number of hPSC lines with gene mutations, for the in vitro modeling of human diseases with complex genotypes and phenotypes. hPSCs with disease-specific mutations have application for use in cardiovascular clinical care.

Novel biomarkers can distinguish between left and right ventricular hypertrophy/failure. Novel biomarkers can distinguish left ventricular hypertrophy/failure from right ventricular hypertrophy/failure, assess right ventricular disease severity, and potentially identify maladaptive changes in RV size, function, and architecture.

In both healthy and pathological cardiovascular tissues, scRNA-seq has enabled the characterization of heterogeneous cell subpopulations with distinct genetic profiles. These can shed light on the pathological mechanisms underlying atherosclerosis and suggest new potential treatments for calcific aortic valve disease.

Numerous ncRNAs, including miR-93, miR-340, miR-433, miR-765, CHROME, and large epigenetic changes in DNA methylation have been linked to atherogenesis in endothelial, smooth muscle, and macrophage cells. In pro-inflammatory macrophages of the human carotid plaque, elevated HDAC9 was related to matrix metalloproteinase 1 (MMP1) and MMP2 production, while decreased HDAC9 was seen to promote resolution of inflammation and reverse cholesterol transfer, which may halt or reverse the disease process. [10]

Neurological Diseases

Over the past years, more attention has been paid to personalized medicine due to the unexpected failure of disease treatment and lack of response in patients or increased side effects in an individual. Also, the use of genetic markers for designing treatments is of great importance. In a clinical test, the APOE-ε4 allele was selected as a biomarker for early diagnosis of Alzheimer Disease using modern biomarker analysis tools. [11]

Infectious Diseases

During the last decades, Hepatitis C has, as standard procedure, been treated with a combination of pegylated-interferon-α (PEG-INF) and Ribavirin (Gatselis, Zachou et al. 2014). The outcome of this treatment is suboptimal in genotype 1 Hepatitis C patients and is associated with severe adverse side effects. Over 40 genes have already been identified to modulate, but research has mainly focused on two SNPs: interleukin 28B (IL28B) and inosine triphosphatase (ITPA). IL28B genotype can, together with a specific biomarker, identify patients who are most likely to undergo spontaneous clearance and those in need of early antiviral therapy. The ITPA gene-related research mainly focused on a reduction of anemia as an adverse side effect of RBV treatment. Yet the effect of ITPA SNPs on therapeutic outcomes is still unclear and deserves further attention in research (Gatselis, Zachou et al. 2014). Nonetheless, major advancements have been made in therapy: in 2014 and 2015 several new medicinal products entered the market. The combination of Ledipasvir and Sofosbuvir was a major breakthrough for the treatment of genotype 1 virus infected patients (Zhang, Nguyen et al. 2016). IL28B non-CC genotype has been associated with lower response rates to interferon-based therapies.

METHODOLOGIES OF PERSONALIZED MEDICINE

Genomic Sequencing Techniques



Fig 5. An overview of whole genome sequencing (WGS), whole exome sequencing (WES) and static gene panel techniques.

Bioinformatics Tools and Data Analysis

These approaches can help to transform biomedical data into useful drug development information, and to apply the knowledge for decision support in clinical practice. Today, data integration techniques related to the field of biomedical sciences and health care settings are rapidly revolutionizing research domains by acting as a bridge between biological and medical sciences and data mining. This certainly rests upon a record data upsurge in biological knowledge and research. In the modern era, the field of bioinformatics is facing a challenging task to handle and interpret the massive amounts of genomics, proteomics, and metabolomics data, which are accumulating at an unprecedentedly fast pace. Sparse, noisy, and discontinuous data need special care, which is difficult using traditional machine learning and existing computational methods. Numerous promising solutions have been exploited to tackle big data mining problems and provide creative solutions. In this sense, we must consider that there is no single solution for any biomedical problem. As we have stated in the conceptualization of big data section, there could be infinite models that solve a biomedical problem due to the huge uncertainty space. One of the possible approaches to deal with this ill-posed problem is to sample the uncertainty space using a wide multeity of models. There is no unique model capable of solving this problem perfectly, so we need to explore different techniques, obtaining a solution with its uncertainty assessment, using a consensus strategy. This way, we could give robust information to a medical expert to enhance the medical decision process. There are multiple applications of this methodology in the field of proteomics, genomics, clinical prognosis, cancer treatment, aging, analysis of defective pathways and drug repositioning. The idea is to benefit from biomedical data and apply resourceful informatics approaches to reform the practice of medicine and to improve the health care system. Implementing these approaches promises a bright era of next generation precision medicine. Research strategies that facilitate up-to-date all-encompassing biomedical expertise along with handling vast health care data are highly required.

Although big data analysis promises great advantages and a potential solution to a diverse range of problems, there remain many unique technical, computational, and statistical challenges that must be addressed to fully explore its potential. Heterogeneity, incompleteness, complexity, privacy problems, scalability, lack of structure, storage bottlenecks, spurious correlations, incidental endogeneity, noise accumulation, experimental variations, statistical biases, and measurement errors impede progress at all phases of the big data analysis from data collection and analysis to result in elucidation that can create value from the data. In order to solve this issue, data structuring should be the first key step in, or prior, to data analysis. [12]

Clinical Implementation

1. Health policies

• Setting in motion toward legislative measures (i.e., existing project or initiative to reach this aim), Legislation/regulation, Collaborative working groups among the different stakeholders.

2. Integration of PM in the health system

• Portfolio of PM services, Level of accessibility of PM in the health system, Portfolio of purpose of care.

3. Basic research and translation
• Plan for the promotion of basic research in PM and translation to clinical research.
4. Infrastructures and resources
• Projects for gathering omics information at the population level, Biobanks (biological samples at the population or pathology-specific level), Electronic health record storage platforms, Omics data storage platforms, Omics data and big data analysis platforms.
5. Data management and availability
• Harmonization, quality, and protection of electronic health records, Harmonization, quality, and protection of omics data, Incorporation of omics data into electronic health records, Access to omics data of and interoperability among practitioners and entities, Use of omics data in clinical decision-making.
6. Organizational areas
• Interoperability among basic and translational research organizations and resources, Introduction of areas specializing in PM, Reinforcement of non-specialized areas involved in PM, Development and adoption of procedural guidelines, Organizational structure of omics testing, Omic testing equipment.
7. Ethical, legal, and social implications (ELSI)
• Patient information care level, Standardized patient informed consent forms and/or the patient acceptance and commitment, Data protection mechanisms.
8. Educational needs
• Education and training for healthcare staff specialized and non-specialized in PM, Education of patients and relatives in PM, Awareness-raising and outreach activities for the citizenry.

9. Assessment of health technologies
• PM-specific health technology assessment plan, Health technology assessment body, PM-specific health technology assessment methodology, HTA decision-making group.
10. Assessment of implementation
• PM implementation evaluation plan, Implementation evaluation body, Implementation evaluation methodology.
11. Funding
• PM implementation budget forecast. [13]

FUTURE PROSPECTS OF PERSONALIZED MEDICINE

Advances in Genomic Technologies

Technological advances and the dramatically reduced costs of DNA sequencing have resulted in increasing 'mainstreaming' of genetic testing into routine practice and the prospect of Whole Genome Sequencing becoming part of National Health Services diagnostics. Clinicians need to understand the role of genomic medicine in their specialty, in offering prompt and precise diagnosis for patients and in directing management decisions. Detailed clinical information and multidisciplinary input remains vital for variant interpretation. The knowledge gained from genomics and personalized medical approaches is exciting. A number of applications are in current practice and these are likely to increase exponentially as WGS becomes embedded in routine patient care. Analysis of the evidence, from a clinical and health economic perspective, is pivotal to the ongoing success of the genomics era.

Personalized medicine represents a shift in approach from 'one-size-fits-all' to tailored care and targeted therapies. The application of new technologies, including genomics, enhances our understanding of disease and its molecular mechanisms, and therefore the capacity for personalized interventions. Increasingly, other testing modalities will contribute, including transcriptomics (RNA-based testing), metabolomics (analyzing the metabolites present in an individual) and proteomics (analyzing the entire complement of expressed proteins).

Integration with Other Omics



Multi-omics, an integrative approach within the systems biology framework, is an innovative field that combines various 'omics' technologies to concurrently evaluate multiple strata of biological data. This approach encompasses the synergistic analysis of genomics, transcriptomics, proteomics, and metabolomics, among other omics fields (e.g., microbiomics), employing an array of bioinformatics tools to gain a comprehensive understanding of complex biological systems. The potential benefits of robust multi-omics pipelines are plentiful. They may provide a deep understanding of disease-associated molecular mechanisms, facilitate precision medicine by accounting for individual omics profiles, foster early disease detection and prevention, aid in the discovery of biomarkers crucial for diagnosis, prognosis, and treatment monitoring, and spotlight molecular targets for innovative drug development or the repurposing of existing therapeutics. [14]



Fig 6. An overview of personalized medicine viewed through the lens of systems biology. Personalized health insights or derived from, and are in interdependent on, layers including the genome, transcriptome, proteome, metabolome, and microbiome.

Precision Public Health

PM as a concept seems in contravention to public health. However, long-term goal of both PM and public health is to keep population healthy. In fact, PM by identifying the individual at risk at the earliest and instituted personalized preventive measure may prevent or delay the risk factor or disease. This is what preventive medicine and public health strive to do. However, there are many doubts of its utility at population level due to its predictive value limited to rare diseases, which would not affect the health of the population at large. Data from two large cohort studies observed only marginal gain in the identification of disease as compared to convention risk factors using PM approach. PM can help in better understanding the response of the host to infections or varied response of the antibiotics/antivirals in different individuals in communicable diseases. The whole-genome sequencing of the micro-organism can be used for the identification of genetic relatedness and mapping of the organism and thus helps in genomic surveillance. Drug susceptibility testing before giving antibiotics to individual so as to prevent multidrug resistance and mapping of the same is essential public health activity. [14]

Ethical, Legal and Social Implications

The Human Genome Project, we see a need to expand the scope of work on the ethical, legal and social challenges raised by personalized medicine to account for its growing clinical applications throughout the healthcare system. Fortunately, the fields of bioethics and clinical ethics have rich traditions of addressing issues such as health disparities, patient privacy and the physician–patient relationship. We believe it will be extraordinarily productive to expand the community of scholars working on the ethical, legal and social implications of genomic medicine to include new types of expertise. In particular, those who have worked on health policy and clinical ethics issues unrelated to genomics have much to contribute to ethical, legal and social implications scholarship. Collaborations with health economists, quality experts and implementation scientists could also be extraordinarily productive. The next decade in personalized medicine should be a time of collaborative, proactive work to anticipate and address emerging challenges, including issues such as health disparities, patient privacy and the physician– patient relationship. [15]

CHALLENGES AND COMPLICATIONS

Translational gap

Observers point out that progress in translating molecular-biology breakthroughs into clinical practice ('from bench to bedside') is slow. It is considered essential to encourage healthcare professionals in primary care to embrace new tools, and to foster partnerships between specialists of various disciplines in cross- cutting collaborations.

Data protection, confidentiality and right to information

Both the identification of biomarkers and next-generation sequencing rely heavily on the collection and analysis of very large sets of data ('big data'). This points to the requirement to ensure the confidentiality of sensitive personal information, for instance in the cross-border transfer of data in large research projects, but also in the context of biobanks: although donors are generally anonymized, many biobanks have provisions that participants remain identifiable for research purposes. As donated samples may be used for further research, questions arise as regards ownership of these samples, the issues of informed consent and the right to information, including the right not to know.

Regulatory clarity

Stakeholders have stressed the need for a clear regulatory framework for personalized medicine – to ensure it respects the principle of universal and equal access to healthcare, to avoid discrimination of patients on the basis of genetic data (e.g. by insurance companies or employers), and to regulate genetic/genomic information for commercial purposes.

Cost

Molecularly targeted treatments tend to be expensive since, by definition, they are suitable for only a limited number of patients. From the perspective of payers (public health systems, private insurers), this may raise the question of affordability in a context of strained public health budgets, and of the degree to which these costs could be compensated by efficiency gains.

CASE STUDIES AND CLINICAL TRIALS

Success Stories in Personalized Medicine

Numerous success stories highlight the potential of personalized medicine. Notable examples include targeted therapies for cancer, pharmacogeneric-guided treatments for cardiovascular disease, and personalized interventions for rare genetic disorders. These case studies demonstrate the tangible benefits of personalized medicine in improving patient outcomes.

Ongoing Research and Trials

Ongoing research efforts continue to explore the value of personalized medicine. The FDA's Division of Translational and Precision Medicine (DTPM) is a team of translational scientists with expertise in clinical pharmacology, human genomics, epidemiology, and molecular biology. In general, its goals include confirming that clinical pharmacology principles and precision medicine strategies are utilized properly in all phases of drug development to expand benefit and diminish risk to patients. The DTPM notes that the goals of precision medicine include progressing the expansion and accessibility of safe and effective targeted treatments while also fostering scientific research efforts to integrate omics-based tools, technologies, and biomarkers in drug development. The DTPM focuses on the incorporation of genomics, advancement of targeted therapies, and support of biomarker qualification across therapeutic areas, and they execute these applications via their fundamental operational functions, which include the following:

1.Regulatory Review: In the assessment of intrinsic and extrinsic factors on drug exposure, safety, and efficacy and to assist and hasten the advancement of drugs and biological products, DTPM reviewers employ pharmacogenomic, pharmacokinetic, and pharmacodynamic principles.

2.Regulatory Science: DTPM performs research projects and works with researchers throughout government, academia, and industry to identify and address knowledge gaps. To enhance patient care, the researchers concentrate on approaches to expand effectiveness in drug development by utilizing biomarkers, genomics, and pharmacokinetic/pharmacodynamic data.

3.Guidance and Policy Development: DTPM acts to recognize evolving issues in drug development to inform stakeholders on FDA's current philosophy through guidance and policy development.

4.Education and Outreach: Via public workshops, conferences, and other partnerships, DTPM spreads awareness of drug discovery and development with the community. [16]

N-of-1 trials, also called "personalized trials," employ a repeated crossover design in a single patient to allow direct comparison of treatment effects in the participant. Treatment order is preferably randomized and the repetition of treatment periods improves the ability to distinguish more precise differences in the estimates of treatment effects within the participant. Many design elements, including blinding, protocolized and objective outcome assessment, and washout periods between treatments, may be borrowed from traditional parallel group trials to minimize bias. Bayesian analyses may also be used to identify the probability of benefit, which is not directly assessed from conventional frequentist analyses. As interventions are alternated, data are systematically collected on the individual's response to the interventions, allowing for an unbiased comparison of treatment effects that can directly inform treatment decisions for the individual. When a series of these trials are conducted in similar patients, the results can be aggregated across the participants to produce population-level estimates of treatment effects. [17]

CONCLUSION

Personalized medicine represents a paradigm shift in healthcare, offering the potential to tailor treatments to individual genetic profiles. Advances in genomic technologies, bioinformatics, and clinical implementation have paved the way for personalized approaches to disease prevention, diagnosis, and treatment. However, challenges remain in ensuring equitable access, addressing ethical considerations, and overcoming technical and economic barriers. The future of personalized medicine lies in the continued integration of genomic insights with other omics fields, the application of precision public health strategies, and the development of innovative therapies. By embracing these advancements and addressing the associated challenges, personalized medicine has the potential to significantly improve patient outcomes and revolutionize healthcare.

Declaration by Authors

Ethical Approval: Nil

Acknowledgement: None

Source of Funding: None

Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013 Sep-Oct;16(6 Suppl):S4-9. doi: 10.1016/j.jval.2013.06.005. PMID: 24034312.
2. Sharma H, Bhadouria U, Dhiman S, Sharma T, Chatterjee A, Kumar P. An Updated Overview on Personalized Medicine: The Next-Gen Paradigm. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):457-463.
3. Delpierre C, Lefèvre T. Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front. Sociol.2023, 8:1112159. doi: 10.3389/fsoc.2023.1112159.
4. Pravin B, Kishore O, Ashwini B. Personalized medicine: the future of Modern Medicine. Authorea. 2021, 1-9.
5. Amruta P, Aniruddha A, Swarupa D, Sanjivani S, Tushar A. Review on Personalized Medicine, International Journal of Novel Research and Development. 2022; 7(9): 2456-4184.
6. Evers AW, Rovers MM, Kremer JA, Veltman JA, Schalken JA, Bloem BR, van Gool AJ. An integrated framework of personalized medicine: from individual genomes to participatory health care. Croat Med J. 2012 Aug;53(4):301-3. doi: 10.3325/cmj.2012.53.301. PMID: 22911520; PMCID: PMC3428816.
7. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006. PMID: 29935653; PMCID: PMC6366451.
8. Adeniji AA, Dulal S, Martin MG. Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo. World J Oncol. 2021 Jun;12(2-3):50-60. doi: 10.14740/wjon1345. Epub 2021 May 14. PMID: 34046099; PMCID: PMC8139741.
9. Hoeben A, Joosten EAJ, van den Beuken-van Everdingen MHJ. Personalized Medicine: Recent Progress in Cancer Therapy. Cancers (Basel). 2021 Jan 11;13(2):242. doi: 10.3390/cancers13020242. PMID: 33440729; PMCID: PMC7826530.
10. Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A, Goel A, Chopra H, Cavalu S. Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review. J Clin Med. 2023 Feb 23;12(5):1799. doi: 10.3390/jcm12051799. PMID: 36902588; PMCID: PMC10003116.
11. Zare Chavoshy, H., Barati, F., & Ghasemi, R. Personalized Medicine Approach in the Treatment of Alzheimer's Disease. Personalized Medicine Journal. 2022, 7(26), 30-33. doi: 10.22034/pmj.2022.697001.
12. Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, Fernández-Brillet L, Fernández-Martínez JL, Kloczkowski A. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. Int J Mol Sci. 2022 Apr 22;23(9):4645. doi: 10.3390/ijms23094645. PMID: 35563034; PMCID: PMC9104788.
13. Aguilera-Cobos L, García-Sanz P, Rosario-Lozano MP, Claros MG, Blasco-Amaro JA. An innovative framework to determine the implementation level of personalized medicine: A systematic review. Front Public Health. 2023 Feb 3;11:1039688. doi: 10.3389/fpubh.2023.1039688. PMID: 36817923; PMCID: PMC9936069.
14. Mohr AE, Ortega-Santos CP, Whisner CM, Klein-Seetharaman J, Jasbi P. Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare. Biomedicines. 2024 Jul 5;12(7):1496. doi: 10.3390/biomedicines12071496. PMID: 39062068; PMCID: PMC11274472.
15. Yadav AK, Sagar R. Precision medicine in public health in India: Nascent but poised in the right direction. Indian J Public Health. 2021 Oct-Dec;65(4):414-417. doi: 10.4103/ijph.ijph_1728_21. PMID: 34975090.
16. Yuette CT. Advancing Research in Personalized Medicine. US Pharm. 2023; 48(2): 31-36.
17. Samuel JP, Wootton SH, Tyson JE. N-of-1 trials: The epitome of personalized medicine? J Clin Transl Sci. 2023 Jul 3;7(1):e161. doi: 10.1017/cts.2023.583. PMID: 37528940; PMCID: PMC10388431